secwatch / observer
8-K filed July 21, 2022, 7:59 PM ET ticker CLCS CIK 0001569340
leadership confidence high sentiment negative materiality 0.50

Two directors resign from Cell Source board, no disagreements cited

Cell Source, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Zolty

director
CLCS · Cell Source, Inc.
Effective
2022-07-18
Filed
July 21, 2022, 7:59 PM ET
On July 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of Cell Source, Inc. (the “Company”).
Departed

Ben Friedman

director
CLCS · Cell Source, Inc.
Effective
2022-07-18
Filed
July 21, 2022, 7:59 PM ET
On July 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of Cell Source, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Zolty resigned as director at Cell Source, Inc..

Action
resigned
Role
director
Exact text from the filing
On July 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of Cell Source, Inc. (the “Company”).
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Ben Friedman resigned as director at Cell Source, Inc..

Action
resigned
Role
director
Exact text from the filing
On July 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of Cell Source, Inc. (the “Company”).
View on SEC.gov

Cell Source, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-22-019997
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.